Citigroup’s Aurinia Pharmaceuticals AUPH Stock Holding History

Citigroup’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-50,000	Closed	-$424K	–	6078
2025 Q2	$424K	Buy	+50,000	New	+$401K	﹤0.01%	3727
2025 Q1	–	Sell	-50,000	Closed	-$449K	–	5572
2024 Q4	$449K	Buy	50,000 +30,000	+150%	+$245K	﹤0.01%	3904
2024 Q3	$147K	Sell	20,000 -29,900	-60%	-$185K	﹤0.01%	4566
2024 Q2	$285K	Hold	49,900	–	–	﹤0.01%	3708
2024 Q1	$250K	Buy	+49,900	New	+$339K	﹤0.01%	3904
2023 Q4	–	Sell	-40,000	Closed	-$311K	–	5694
2023 Q3	$311K	Sell	40,000 -9,900	-20%	-$96.8K	﹤0.01%	3397
2023 Q2	$483K	Buy	+49,900	New	+$518K	﹤0.01%	3403

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citigroup's AUPH Position: Q2 2026 in Review

Citigroup increased its Aurinia Pharmaceuticals (AUPH) stake by 348% in Q2 2026, buying an estimated $867K and bringing the position to 69,858 shares worth $1.19M. The position accounts for ﹤0.01% of the portfolio, ranked #3321.

Citigroup first reported a position in AUPH in Q4 2014 and has held it in 41 quarters since. The position peaked at $17.6M in Q4 2021. 283 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

Citigroup held 69,858 shares of Aurinia Pharmaceuticals worth $1.19M as of Q2 2026.
Citigroup bought 54,254 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $867K.
Aurinia Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3321 holding.
Citigroup first reported a position in Aurinia Pharmaceuticals in Q4 2014 and has held it in 41 quarters since.
Citigroup's Aurinia Pharmaceuticals position peaked at $17.6M in Q4 2021.
283 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.